Summary

The 7 major autism spectrum disorder markets are expected to exhibit a CAGR of 5.31% during 2024-2034.

The autism spectrum disorder market has been comprehensively analyzed in IMARC's new report titled "Autism Spectrum Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Autism spectrum disorder (ASD) refers to a neurodevelopmental condition that affects communication, social interaction, and behavior. It is called a "spectrum" disorder because it can manifest differently in each individual, with varying degrees of severity and symptoms. Some of the common characteristics of the ailment include difficulty with social interactions, communication challenges, repetitive behaviors or routines, sensory sensitivities, etc. Individuals may also have trouble with verbal and nonverbal communication, struggle with maintaining eye contact, and exhibit intense interest in specific topics or objects. Additionally, they may engage in repetitive behaviors like rocking back and forth or hand-flapping and have sensory sensitivities to bright lights or loud noises. Diagnosing ASD typically involves a developmental screening, followed by a diagnostic evaluation that includes detailed assessments of the individual's communication, social interaction, and behavior. These evaluations consist of direct observation, standardized tests, interviews with caregivers and family members, and medical and genetic testing.

The increasing cases of various genetic or chromosomal conditions, such as tuberous sclerosis and fragile X syndrome, are primarily driving the autism spectrum disorder market. Apart from this, the rising prevalence of numerous risk factors that contribute to the onset of the ailment, including abnormal brain development, immune system dysfunction, complications during pregnancy or delivery, etc., is further bolstering the market growth. Moreover, the widespread adoption of several medications, such as antipsychotics, antidepressants, stimulants, etc., for managing some of the symptoms associated with the ailment, like anxiety, depression, hyperactivity, etc., is also creating a positive outlook for the market. Additionally, the escalating demand for applied behavior analysis (ABA) therapy, since it is effective in improving social skills, communication, and behavior in children having ASD, is acting as a significant growth-inducing factor. Furthermore, the emerging popularity of sensory integration therapy, which involves exposing individuals with ASD to various sensory experiences, such as touch, sound, and movement, in order to help them better process and integrate sensory information, is expected to drive the autism spectrum disorder market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the autism spectrum disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for autism spectrum disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the autism spectrum disorder market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the autism spectrum disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the autism spectrum disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current autism spectrum disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the autism spectrum disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the autism spectrum disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the autism spectrum disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of autism spectrum disorder across the seven major markets?
What is the number of prevalent cases (2018-2034) of autism spectrum disorder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of autism spectrum disorder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with autism spectrum disorder across the seven major markets?
What is the size of the autism spectrum disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of autism spectrum disorder?
What will be the growth rate of patients across the seven major markets?

Autism Spectrum Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for autism spectrum disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the autism spectrum disorder market?
What are the key regulatory events related to the autism spectrum disorder market?
What is the structure of clinical trial landscape by status related to the autism spectrum disorder market?
What is the structure of clinical trial landscape by phase related to the autism spectrum disorder market?
What is the structure of clinical trial landscape by route of administration related to the autism spectrum disorder market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Autism Spectrum Disorder - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence

5 Autism Spectrum Disorder - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Autism Spectrum Disorder - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (​2018-2034​)
7.2.4 Epidemiology by Gender (​2018-2034​)
7.2.5 Diagnosed Cases (​2018-2034​)
7.2.6 Patient Pool/Treated Cases (​2018-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (​2018-2034​)
7.3.4 Epidemiology by Gender (​2018-2034​)
7.3.5 Diagnosed Cases (​2018-2034​)
7.3.6 Patient Pool/Treated Cases (​2018-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (​2018-2034​)
7.4.4 Epidemiology by Gender (​2018-2034​)
7.4.5 Diagnosed Cases (​2018-2034​)
7.4.6 Patient Pool/Treated Cases (​2018-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (​2018-2034​)
7.5.4 Epidemiology by Gender (​2018-2034​)
7.5.5 Diagnosed Cases (​2018-2034​)
7.5.6 Patient Pool/Treated Cases (​2018-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (​2018-2034​)
7.6.4 Epidemiology by Gender (​2018-2034​)
7.6.5 Diagnosed Cases (​2018-2034​)
7.6.6 Patient Pool/Treated Cases (​2018-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (​2018-2034​)
7.7.4 Epidemiology by Gender (​2018-2034​)
7.7.5 Diagnosed Cases (​2018-2034​)
7.7.6 Patient Pool/Treated Cases (​2018-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (​2018-2034​)
7.8.4 Epidemiology by Gender (​2018-2034​)
7.8.5 Diagnosed Cases (​2018-2034​)
7.8.6 Patient Pool/Treated Cases (​2018-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (​2018-2034​)
7.9.4 Epidemiology by Gender (​2018-2034​)
7.9.5 Diagnosed Cases (​2018-2034​)
7.9.6 Patient Pool/Treated Cases (​2018-2034​)

8 Autism Spectrum Disorder - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Autism Spectrum Disorder - Unmet Needs

10 Autism Spectrum Disorder - Key Endpoints of Treatment

11 Autism Spectrum Disorder - Marketed Products
11.1 List of Autism Spectrum Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets

Kindly note that the complete list of marketed drugs has been provided in the report.

12 Autism Spectrum Disorder - Pipeline Drugs
12.1 List of Autism Spectrum Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 STP1 - Stalicla SA
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 ML 004 - MapLight Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 RO 7017773 - Roche
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 L179 - Yamo Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. Autism Spectrum Disorder - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Autism Spectrum Disorder – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Autism Spectrum Disorder - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Autism Spectrum Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Autism Spectrum Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Autism Spectrum Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Autism Spectrum Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Autism Spectrum Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Autism Spectrum Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Autism Spectrum Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Autism Spectrum Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Autism Spectrum Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Autism Spectrum Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Autism Spectrum Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Autism Spectrum Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Autism Spectrum Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Autism Spectrum Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Autism Spectrum Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Autism Spectrum Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Autism Spectrum Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Autism Spectrum Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Autism Spectrum Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Autism Spectrum Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Autism Spectrum Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Autism Spectrum Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Autism Spectrum Disorder - Access and Reimbursement Overview

16 Autism Spectrum Disorder - Recent Events and Inputs From Key Opinion Leaders

17 Autism Spectrum Disorder Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Autism Spectrum Disorder Market – Strategic Recommendations

19 Appendix